DoW Bone Marrow Failure, Idea Development Award

The Bone Marrow Failure Research Program Idea Development Award (IDAs) under solicitation HT942526BMFRPIDA is a competitive research grant opportunity designed to foster innovative, high-impact scientific ideas aimed at advancing the understanding and eventual cure of bone marrow failure diseases. Open to both Established Investigators and Early-Career Investigators, the award explicitly does not require preliminary data, placing emphasis on the scientific soundness, creativity, and feasibility of the proposed approach in the absence of existing supporting evidence. Applicants must structure their proposals around clearly defined components including a 10-page Project Narrative, a 4-page Statement of Work, and several one-page statements covering Innovation, Impact, Translation Potential, and, for Early-Career Investigators, an eligibility certification. The maximum funding available is $800,000 over a three-year performance period, with strict limits on allowable costs including travel, and a complete exclusion of clinical trial expenses. Evaluation is based on seven equally weighted peer review criteria: Research Strategy and Feasibility, Innovation, Impact, Personnel, Research Sharing Plan, Translation Potential, and Budget, all assessed qualitatively without numerical weighting. Foreign affiliation disclosures are mandatory for all senior personnel, with non-disclosure leading to disqualification, and all awardees must comply with national security requirements under NSPM-33, including risk mitigation via the DOD Component Decision Matrix. Proposals must be submitted electronically through eBRAP for intramural applicants or Grants.gov for extramural applicants by November 4, 2026, using specific PDF file naming conventions and must include certifications on Unique Entity Identifier registration in SAM, Current/Pending Support, and Biographical Sketches. Organizations receiving over $10 million in cumulative federal awards must also comply with semiannual reporting obligations in SAM.gov, and award transfers are prohibited during the final year of performance. The award operates under a trade-off selection process prioritizing scientific merit over cost, and administration is handled through the Department of the Army’s USAMRAA under the Defense Health Agency Contracting Activity, with compliance guided by CDMRP directives and NIH-style formatting requirements.